214 related articles for article (PubMed ID: 20591690)
1. Voriconazole exposure and geographic location are independent risk factors for squamous cell carcinoma of the skin among lung transplant recipients.
Vadnerkar A; Nguyen MH; Mitsani D; Crespo M; Pilewski J; Toyoda Y; Bermudez C; Kwak EJ; Silveira FP; Clancy CJ
J Heart Lung Transplant; 2010 Nov; 29(11):1240-4. PubMed ID: 20591690
[TBL] [Abstract][Full Text] [Related]
2. Increased incidence of cutaneous squamous cell carcinoma in lung transplant recipients taking long-term voriconazole.
Feist A; Lee R; Osborne S; Lane J; Yung G
J Heart Lung Transplant; 2012 Nov; 31(11):1177-81. PubMed ID: 22841559
[TBL] [Abstract][Full Text] [Related]
3. Duration of voriconazole exposure: an independent risk factor for skin cancer after lung transplantation.
Zwald FO; Spratt M; Lemos BD; Veledar E; Lawrence C; Marshall Lyon G; Chen SC
Dermatol Surg; 2012 Aug; 38(8):1369-74. PubMed ID: 22551390
[TBL] [Abstract][Full Text] [Related]
4. High cumulative dose exposure to voriconazole is associated with cutaneous squamous cell carcinoma in lung transplant recipients.
Singer JP; Boker A; Metchnikoff C; Binstock M; Boettger R; Golden JA; Glidden DV; Arron ST
J Heart Lung Transplant; 2012 Jul; 31(7):694-9. PubMed ID: 22484291
[TBL] [Abstract][Full Text] [Related]
5. Phototoxicity and photocarcinogenesis associated with voriconazole.
Epaulard O; Leccia MT; Blanche S; Chosidow O; Mamzer-Bruneel MF; Ravaud P; Thiebaut A; Villier C; Lortholary O
Med Mal Infect; 2011 Dec; 41(12):639-45. PubMed ID: 22055586
[TBL] [Abstract][Full Text] [Related]
6. Immunosuppressive level and other risk factors for basal cell carcinoma and squamous cell carcinoma in heart transplant recipients.
Fortina AB; Piaserico S; Caforio AL; Abeni D; Alaibac M; Angelini A; Iliceto S; Peserico A
Arch Dermatol; 2004 Sep; 140(9):1079-85. PubMed ID: 15381547
[TBL] [Abstract][Full Text] [Related]
7. Multiple aggressive squamous cell carcinomas associated with prolonged voriconazole therapy in four immunocompromised patients.
Epaulard O; Saint-Raymond C; Villier C; Charles J; Roch N; Beani JC; Leccia MT
Clin Microbiol Infect; 2010 Sep; 16(9):1362-4. PubMed ID: 19930272
[TBL] [Abstract][Full Text] [Related]
8. Voriconazole and sirolimus coadministration after allogeneic hematopoietic stem cell transplantation.
Marty FM; Lowry CM; Cutler CS; Campbell BJ; Fiumara K; Baden LR; Antin JH
Biol Blood Marrow Transplant; 2006 May; 12(5):552-9. PubMed ID: 16635790
[TBL] [Abstract][Full Text] [Related]
9. Multifocal squamous cell carcinomas in an HIV-infected patient with a long-term voriconazole therapy.
Brunel AS; Fraisse T; Lechiche C; Pinzani V; Mauboussin JM; Sotto A
AIDS; 2008 Apr; 22(7):905-6. PubMed ID: 18427212
[No Abstract] [Full Text] [Related]
10. Voriconazole-associated myositis.
Shanmugam VK; Matsumoto C; Pien E; Rosen J; Kumar P; Whelton S; Steen V
J Clin Rheumatol; 2009 Oct; 15(7):350-3. PubMed ID: 20009971
[TBL] [Abstract][Full Text] [Related]
11. Voriconazole exposure and the risk of cutaneous squamous cell carcinoma in allogeneic hematopoietic stem cell transplant patients.
Wojenski DJ; Bartoo GT; Merten JA; Dierkhising RA; Barajas MR; El-Azhary RA; Wilson JW; Plevak MF; Hogan WJ; Litzow MR; Patnaik MM; Wolf RC; Hashmi SK
Transpl Infect Dis; 2015 Apr; 17(2):250-8. PubMed ID: 25661996
[TBL] [Abstract][Full Text] [Related]
12. Risk-adjusted relationship between voriconazole utilization and non-melanoma skin cancer among lung and heart/lung transplant patients.
McLaughlin JM; Equils O; Somerville KT; Aram JA; Schlamm HT; Welch VL; Mardekian J; Barbers RG
Transpl Infect Dis; 2013 Aug; 15(4):329-43. PubMed ID: 23489832
[TBL] [Abstract][Full Text] [Related]
13. Severe photosensitivity causing multifocal squamous cell carcinomas secondary to prolonged voriconazole therapy.
McCarthy KL; Playford EG; Looke DF; Whitby M
Clin Infect Dis; 2007 Mar; 44(5):e55-6. PubMed ID: 17278050
[TBL] [Abstract][Full Text] [Related]
14. Immunosuppressive treatment after solid organ transplantation and risk of post-transplant cutaneous squamous cell carcinoma.
Ingvar A; Smedby KE; Lindelöf B; Fernberg P; Bellocco R; Tufveson G; Höglund P; Adami J
Nephrol Dial Transplant; 2010 Aug; 25(8):2764-71. PubMed ID: 19729465
[TBL] [Abstract][Full Text] [Related]
15. Voriconazole-associated phototoxicity.
Riahi RR; Cohen PR
Dermatol Online J; 2011 Feb; 17(2):15. PubMed ID: 21382298
[TBL] [Abstract][Full Text] [Related]
16. Voriconazole pharmacokinetic variability in cystic fibrosis lung transplant patients.
Berge M; Guillemain R; Boussaud V; Pham MH; Chevalier P; Batisse A; Amrein C; Dannaoui E; Loriot MA; Lillo-Le Louet A; Billaud EM
Transpl Infect Dis; 2009 Jun; 11(3):211-9. PubMed ID: 19302272
[TBL] [Abstract][Full Text] [Related]
17. Invasive zygomycosis in hematopoietic stem cell transplant recipients receiving voriconazole prophylaxis.
Siwek GT; Dodgson KJ; de Magalhaes-Silverman M; Bartelt LA; Kilborn SB; Hoth PL; Diekema DJ; Pfaller MA
Clin Infect Dis; 2004 Aug; 39(4):584-7. PubMed ID: 15356827
[TBL] [Abstract][Full Text] [Related]
18. [Careful: skins cancers and voriconazole].
Schmutz JL; Trechot P
Ann Dermatol Venereol; 2011 Nov; 138(11):805-6. PubMed ID: 22078051
[No Abstract] [Full Text] [Related]
19. A double-blind trial on prophylactic voriconazole (VRC) or placebo during induction chemotherapy for acute myelogenous leukaemia (AML).
Vehreschild JJ; Böhme A; Buchheidt D; Arenz D; Harnischmacher U; Heussel CP; Ullmann AJ; Mousset S; Hummel M; Frommolt P; Wassmer G; Drzisga I; Cornely OA
J Infect; 2007 Nov; 55(5):445-9. PubMed ID: 17822770
[TBL] [Abstract][Full Text] [Related]
20. Catastrophic squamous cell carcinoma in lung transplant patients treated with voriconazole.
Ibrahim SF; Singer JP; Arron ST
Dermatol Surg; 2010 Nov; 36(11):1752-5. PubMed ID: 20533939
[No Abstract] [Full Text] [Related]
[Next] [New Search]
